| ORIGINAL ARTICLE | |
|
Wuping Bao1, Ping Liu2, Zhongmin Qiu3, Li Yu3, Jingqing Hang4, Xiaohua Gao4, Xin Zhou1
1 Department of Respiratory Medicine, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai 200080, China
2 Department of Respiratory Medicine, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai 200080; Department of Respiratory Medicine, Tongji Hospital, Tongji University, School of Medicine, Shanghai 200065, China
3 Department of Respiratory Medicine, Tongji Hospital, Tongji University, School of Medicine, Shanghai 200065, China
4 Department of Respiratory Medicine, Shanghai Putuo People's Hospital, Shanghai 200060, China
| Date of Submission | 28-Oct-2014 |
| Date of Web Publication | 26-Dec-2014 |
     |
DOI: 10.4103/0366-6999.147805
PMID: 25563311
| Abstract |
Background: The efficacy of montelukast (MONT), a cysteinyl leukotriene receptor antagonist, in nonasthmatic eosinophilic bronchitis (NAEB), especially its influence on cough associated life quality is still indefinite. We evaluated the efficacy of MONT combined with budesonide (BUD) as compared to BUD monotherapy in improving life quality, suppressing airway eosinophilia and cough remission in NAEB.
Methods: A prospective, open-labeled, multicenter, randomized controlled trial was conducted. Patients with NAEB (aged 18-75 years) were randomized to inhaled BUD (200 μg, bid) or BUD plus oral MONT (10 μg, qn) for 4 weeks. Leicester cough questionnaire (LCQ) life quality scores, cough visual analog scale (CVAS) scores, eosinophil differential ratio (Eos), and eosinophil cationic protein (ECP) in induced sputum were monitored and compared.
Results: The control and MONT groups contained 33 and 32 patients, respectively, with similar baseline characteristics. Significant with-in group improvement in CVAS, LCQ scores, Eos, and ECP was observed in both groups during treatment. After 2-week treatment, add-on treatment of MONT was significantly more effective than BUD monotherapy for CVAS decrease and LCQ scores improvement (both P - 0.05). Similar results were seen at 4-week assessment (both P - 0.05). 4-week add-on therapy of MONT also resulted in a higher percentage of patients with normal sputum Eos (-2.5%) and greater decrease of ECP (both P - 0.05).
Conclusions: MONT combined with BUD was demonstrated cooperative effects in improvement of life quality, suppression of eosinophilic inflammation, and cough remission in patients with NAEB.
Methods: A prospective, open-labeled, multicenter, randomized controlled trial was conducted. Patients with NAEB (aged 18-75 years) were randomized to inhaled BUD (200 μg, bid) or BUD plus oral MONT (10 μg, qn) for 4 weeks. Leicester cough questionnaire (LCQ) life quality scores, cough visual analog scale (CVAS) scores, eosinophil differential ratio (Eos), and eosinophil cationic protein (ECP) in induced sputum were monitored and compared.
Results: The control and MONT groups contained 33 and 32 patients, respectively, with similar baseline characteristics. Significant with-in group improvement in CVAS, LCQ scores, Eos, and ECP was observed in both groups during treatment. After 2-week treatment, add-on treatment of MONT was significantly more effective than BUD monotherapy for CVAS decrease and LCQ scores improvement (both P - 0.05). Similar results were seen at 4-week assessment (both P - 0.05). 4-week add-on therapy of MONT also resulted in a higher percentage of patients with normal sputum Eos (-2.5%) and greater decrease of ECP (both P - 0.05).
Conclusions: MONT combined with BUD was demonstrated cooperative effects in improvement of life quality, suppression of eosinophilic inflammation, and cough remission in patients with NAEB.
Keywords: Budesonide; Cough; Quality of Life; Montelukast; Bronchitis
| How to cite this article: Bao W, Liu P, Qiu Z, Yu L, Hang J, Gao X, Zhou X. Efficacy of Add-on Montelukast in Nonasthmatic Eosinophilic Bronchitis: The Additive Effect on Airway Inflammation, Cough and Life Quality. Chin Med J 2015;128:39-45 |
| How to cite this URL: Bao W, Liu P, Qiu Z, Yu L, Hang J, Gao X, Zhou X. Efficacy of Add-on Montelukast in Nonasthmatic Eosinophilic Bronchitis: The Additive Effect on Airway Inflammation, Cough and Life Quality. Chin Med J [serial online] 2015 [cited 2015 Jan 24];128:39-45. Available from: http://www.cmj.org/text.asp?2015/128/1/39/147805 |
No comments:
Post a Comment